Financial reports
10-K
2023 FY
Annual report
11 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
23 Mar 22
10-Q
2021 Q3
Quarterly report
12 Nov 21
Current reports
8-K
Cost Associated with Exit or Disposal Activities
12 Apr 24
8-K
Other Events
29 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Mar 24
8-K
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
11 Mar 24
8-K
Other Events
14 Feb 24
8-K
Departure of Directors or Certain Officers
25 Jan 24
8-K
Other Events
4 Jan 24
8-K
Departure of Directors or Certain Officers
11 Dec 23
8-K
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
11 Dec 23
8-K
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
14 Nov 23
Registration and prospectus
S-1/A
IPO registration (amended)
2 Apr 24
S-1
IPO registration
15 Mar 24
S-1
IPO registration
11 Dec 23
D
$4.74 mm in equity / options / securities to be acquired, sold $4.74 mm, 1 investor
3 Nov 23
424B5
Prospectus supplement for primary offering
30 Oct 23
S-8
Registration of securities for employees
31 Jul 23
424B5
Prospectus supplement for primary offering
14 Apr 23
S-8
Registration of securities for employees
15 Jul 22
S-8
Registration of securities for employees
30 Jul 21
S-8
Registration of securities for employees
30 Jul 21
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEF 14C
Information statement
13 Mar 23
PRE 14C
Preliminary information
3 Mar 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
PRE 14A
Preliminary proxy
19 Apr 22
PX14A6G
Letter to shareholders
15 Jun 21
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
Other
UPLOAD
Letter from SEC
6 Sep 23
CORRESP
Correspondence with SEC
28 Aug 23
UPLOAD
Letter from SEC
23 Aug 23
EFFECT
Notice of effectiveness
25 May 21
CORRESP
Correspondence with SEC
20 May 21
UPLOAD
Letter from SEC
28 Apr 21
EFFECT
Notice of effectiveness
7 Dec 20
CORRESP
Correspondence with SEC
2 Dec 20
UPLOAD
Letter from SEC
2 Nov 20
EFFECT
Notice of effectiveness
1 Oct 19
Ownership
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
3
JAMES B MURPHY
12 Feb 24
4
Change in insider ownership
3 Jan 24
3
Peter Carney
19 Dec 23
4
MICHAEL J ZELEFSKY
7 Jul 23
4
Adam J. Chill
7 Jul 23
4
LINDSAY A MD ROSENWALD
7 Jul 23
4
MICHAEL S WEISS
7 Jul 23
4
Neil Herskowitz
7 Jul 23
4
Manuel MD Litchman
7 Jul 23